The phase Ib clinical trial with PBTZ169 (multiple ascending doses) officially started, dose escalation will be performed through four panels A, B, C and D.
The phase Ib clinical trial with PBTZ169 (multiple ascending doses) officially started, dose escalation will be performed through four panels A, B, C and D.
To evaluate the efficacy of PBTZ169 in combination with a range of other anti-tuberculosis (TB) drugs, our collaborators from the Cole lab, at the Global Health Institute of the EPFL, used in vitroassays and mouse models in order to design a new regimen against active TB. Notably, synergism could be observed when PBTZ169 was applied in combination with bedaquiline, clofazimine, delamanid and sutezolid.
Read MorePBTZ169 has been named Macozinone. Read more here.
The phase Ia clinical trial with PBTZ169 is completed and the collected safety data, as well as pharmacokinetic and pharmacodynamic parameters, are being analyzed.
The first three investigation panels of the Phase Ia clinical trial have been successfully completed. The fourth and final panel has started and healthy male volunteer recruitment is complete.
2017 has been an exciting year during which the iM4TB Foundation made many accomplishments. Pre-clinical trials were successfully completed with PBTZ169 continuing to show all its earlier promise at being a new cure for tuberculosis. Phase Ia of clinical trials was approved by Swissmedic and are moving ahead at the CHUV; this was largely made possible by a very generous donation from the Bill and Melinda Gates Foundation.
Read MoreThis is a randomized, double-blind, placebo-controlled, single ascending dose study conducted at one study center in Switzerland.
Four panels (A, B, C and D) of 8 male subjects (6 active and 2 placebo) each undergoing two investigation periods and receiving either single doses of PBTZ169 at increasing dose levels or a matching placebo. Subjects will participate in only one panel. Blocks of 4 subjects (3 under active treatment, 1 under placebo) will be investigated in parallel. Panels A and B are interleaved.
Read MoreOn October 13, 2017, Professor Stewart Cole was appointed President of the Institut Pasteur by its Board of Directors for a four-year term. He will take office in January 2018.
The Bill & Melinda Gates foundation has awarded EPFL-based non-profit iM4TB USD 2.45 million to take their innovative anti-tuberculosis drug PBTZ169 into clinical trials.
NEARMEDIC Plus wins the silver medal of the Suvorov Prize 2015.